XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Significant agreements - Novartis Collaboration Agreement (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 27, 2023
USD ($)
item
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Significant agreements.              
Maximum days allowed for cancellation of contracts prior written notice       90 days      
Revenue from collaborative arrangement   $ 2,676 $ 5,352 $ 31,567 $ 21,645    
Deferred revenue   109,191   109,191   $ 135,194 $ 61,873
Termination in entirety or product by product or target by target basis              
Significant agreements.              
Threshold period of notice required for termination of agreement 90 days            
Completion of all milestones for targets              
Significant agreements.              
Milestone payments receivable $ 800,000            
Novartis              
Significant agreements.              
Number of collaboration targets | item 2            
Additional research term 1 year            
Upfront cash payment $ 50,000            
Milestone payments receivable 210,000            
Milestone payments, receivable $ 840,000            
Maximum days allowed for cancellation of contracts prior written notice 30 days            
Total transaction price initially determined $ 50,000            
Expected period for satisfaction of performance obligations 3 years            
Material rights exercise period 6 years            
Revenue from collaborative arrangement   1,276 $ 772 6,301 $ 772    
Deferred revenue   45,971   $ 45,971   $ 50,008 $ 0
Novartis | Termination based on other party's uncured material breach or insolvency              
Significant agreements.              
Threshold period of notice required for termination of agreement 60 days            
Novartis | Termination if safety or regulatory issue exists              
Significant agreements.              
Threshold period of notice required for termination of agreement 30 days            
Novartis | Expiration of two material rights associated with limited substitution rights              
Significant agreements.              
Revenue from collaborative arrangement   $ 2,500          
Novartis | Achievement of specified levels of net sales              
Significant agreements.              
Milestone payments receivable $ 200,000